Paul Hudson, chief executive officer of Sanofi, visiting the drugmaker’s exhibition stand at the Viva Technology conference at Porte de Versailles exhibition centre in Paris, France, on Friday. Photograph: Nathan Laine/Bloomberg

Sanofi will invest about €400 million in research and development of next-generation vaccines using mRNA technologies which proved their efficiency in(...)